Skip to main content
Norway
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
  • Aidian – Your aid in diagnostics
  • Produkter
  • Om oss
  • Nyheter
  • Antibiotikaresistens
  • Aidian Academy
  • Messer og utstillinger
  • Kundehistorier
Kontakt oss Søke
Logo
Kontakt oss
  • Pasientnær diagnostikk
  • Mikrobiologi
  • Molekylær mikrobiologi
  • Hygiene overvåking
  • RIA / kollagen
  • Luftveisinfeksjoner
  • Andre
Pasientnær diagnostikk
  • QuikRead go-systemet
  • Certest
  • Nova Biomedical
  • microINR
  • Acro™ Biotech
  • SD BIOSENSOR STANDARD F
  • bioLytical Laboratories INSTI®
  • Hangzhou AllTest Biotech
Les mer
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go tilbehør
QuikRead go
Mikrobiologi
  • Uricult
  • Uricult Vet
  • Cultura M
  • MIKROGEN serologi
  • Meridian Immunoassays
  • Meridian Curian®
  • Reagena
  • Medac EIA
Les mer
Molekylær mikrobiologi
  • Meridian Alethia®
  • Meridian Revogene®
  • MIKROGEN molecular diagnostics
  • SD BIOSENSOR STANDARD M10
Les mer
Hygiene overvåking
  • Easicult
  • Hygicult
  • Clean Card PRO
Les mer
RIA / kollagen
  • UniQ
Les mer
Andre
  • Grifols Promonitor®
  • Narkotika tester
Les mer
  • Aidian i Norge
  • Styre og ledelse
  • Bærekraft
  • Kultur
  • Karriere
  • Nyheter
  • Produktnyheter
  • AMR
  • Hendelser
  • Stories from customers
  • COVID-19
  • Om C-reaktivt protein (CRP)
  • CRP og nedre luftveisinfeksjon (NLI)
  • Undervisningsmateriell
  • QuikRead go CRP-produkter
  • Spredning av antibiotikaresistente bakterier
  • Nyttige lenker
  • Generally
  • Product information
  • Courses
  • Documents and materials
  • Frequently asked questions
  • Søvnhygiene: overvåking av renheten på puter og i sengetøy
  • Sparer både tid og stress
  • Færre feilmeldinger, raske resultater og mindre avfall!
Logo
Kontakt oss Lukk
  • Produkter
    • Pasientnær diagnostikk
      • QuikRead go-systemet
      • Certest
      • Nova Biomedical
      • microINR
      • Acro™ Biotech
      • SD BIOSENSOR STANDARD F
      • bioLytical Laboratories INSTI®
      • Hangzhou AllTest Biotech
    • Mikrobiologi
      • Uricult
      • Uricult Vet
      • Cultura M
      • MIKROGEN serologi
      • Meridian Immunoassays
      • Meridian Curian®
      • Reagena
      • Medac EIA
    • Molekylær mikrobiologi
      • Meridian Alethia®
      • Meridian Revogene®
      • MIKROGEN molecular diagnostics
      • SD BIOSENSOR STANDARD M10
    • Hygiene overvåking
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / kollagen
      • UniQ
    • Luftveisinfeksjoner
    • Andre
      • Grifols Promonitor®
      • Narkotika tester
  • Om oss
    • Aidian i Norge
    • Styre og ledelse
    • Bærekraft
    • Kultur
    • Karriere
  • Nyheter
    • Nyheter
    • Produktnyheter
    • AMR
    • Hendelser
    • Stories from customers
    • COVID-19
  • Antibiotikaresistens
    • Om C-reaktivt protein (CRP)
    • CRP og nedre luftveisinfeksjon (NLI)
    • Undervisningsmateriell
    • QuikRead go CRP-produkter
    • Spredning av antibiotikaresistente bakterier
    • Nyttige lenker
  • Aidian Academy
    • Generally
    • Product information
    • Courses
    • Documents and materials
    • Frequently asked questions
  • Messer og utstillinger
  • Kundehistorier
    • Søvnhygiene: overvåking av renheten på puter og i sengetøy
    • Sparer både tid og stress
    • Færre feilmeldinger, raske resultater og mindre avfall!
Populære produkter
AllTest hCG rapid test

AllTest hCG rapid test

Acro Strep A hurtigtest

Acro Strep A hurtigtest

Acro hCG hurtigtest

Acro hCG hurtigtest

Siste nytt
Se alt

Vi introduserer QuikRead go Plus Instrument!

20. januar 2025 | Nyheter, Produktnyheter

Increase in influenza and RSV activity in the EU/EEA

14. januar 2025 | Nyheter

Webinar: A Point-of-Care analyzer for DOAC testing

25. november 2024 | Hendelser

  • Se alt
  • Ingen resultater
  • Loading...
Nyheter

Vi introduserer QuikRead go Plus Instrument!

20. januar 2025 | Nyheter, Produktnyheter

Increase in influenza and RSV activity in the EU/EEA

14. januar 2025 | Nyheter

Tilbake til alle nyheter
29. november 2023
Nyheter,
Produktnyheter

Benefits of Bladder EpiCheck for bladder cancer surveillance

As November, Bladder Health Month 2023, is coming to an end we want to highlight Bladder Cancer surveillance.

Bladder cancer is the 5th most common cancer in Europe, affecting over 200 000 people yearly.1 Non-muscle-invasive bladder cancer (NMIBC) accounts for the majority of newly diagnosed bladder cancers. With up to 70% of patients experiencing recurrence within 2 years of initial treatment and 10-15% progressing to higher risk cancer, monitoring of bladder cancer is vital.2

The current gold standard methods for bladder cancer surveillance are cystoscopy and cytology. However, they have their limitations as both are based on operator-dependent assessment. Cytology has low to moderate sensitivity, while some types of tumours are easily missed in cystoscopy.2

During the first years after initial treatment, bladder cancer patients undergo as many as 4 cystoscopies a year. Cystoscopy is an invasive and expensive procedure, so the need for an effective biomarker test for surveillance is high.

Bladder EpiCheck® from Nucleix is a urine marker test for monitoring of NMIBC. It uses a panel of 15 DNA methylation markers and is included in the EAU (European Association of Urology) guidelines for bladder cancer surveillance. The guidelines state that Bladder EpiCheck could be used to replace and/or postpone cystoscopy.3

Bladder EpiCheck

A meta-analysis of the diagnostic accuracy of urinary biomarker tests found that Bladder EpiCheck has a high-grade Negative Predictive Value (NPV) of 99 %, high-grade sensitivity of 91 % and specificity of 84 %.4

The results of the test are objective and not affected by BCG treatment, hematuria, or infections.5 The high performance of the test makes it a reliable tool to rule out high-risk recurrence and reduce unnecessary procedures.

Reducing the number of cystoscopies by incorporating Bladder EpiCheck into the surveillance of bladder cancer could lessen the strain on the healthcare system as well as benefit the well-being of patients.

For more detailed information about Bladder EpiCheck, head to the Bladder EpiCheck product site or contact us.

Aidian is the proud distributor of Bladder EpiCheck in the Nordics.


References

  1. European Association of Urology. Bladder Cancer: The Forgotten Cancer. https://uroweb.org/news/bladder-cancer-the-forgotten-cancer. Accessed 27.11.2023.
  2. Biomarkers in the management of non-muscle invasive bladder cancer (NMIBC), BCaMonitor, Updated May 2023.
  3. EAU Non-muscle-invasive Bladder Cancer guidelines 2022. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis
  4. Laukhtina et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021 Dec;4(6):927-942; and corrigendum at Eur Urol Oncol. 2022 Jan 19;S2588-9311(22)00004-9.
  5. Cochetti et al. Urol Onc Nov 2021; Pierconti et al. Urol Onc Nov 2021, Bladder EpiCheck® EU Instructions For Use, 09-May-2022


Share
Facebook
Twitter
E-post

Aidian Norway AS

Nydalsveien 28,
0484 Oslo


(+47) 66 78 56 30


Forespørsler
info@aidian.no


Salg
ordre@aidian.no

Selskap
  • Om oss
  • Bærekraft
  • Karriere
  • Kontakt oss
Produkter
  • Pasientnær diagnostikk
  • Mikrobiologi
  • Molekylær mikrobiologi
  • Hygiene overvåking
  • RIA / kollagen
  • Luftveisinfeksjoner
  • Andre
Hurtiglenke
  • Aidian Academy
Copyright © 2025 Aidian
  • Personvernregler
  • Personvernerklæring
  • Varsel om informasjonskapsler
  • Politikk for sosiale medier